By Kosaku Narioka
Takeda Pharmaceutical is scheduled to report third-quarter results on Thursday. Here's what you need to know:
NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data provider LSEG. That would compare with Y105.7 billion net profit in the year-earlier period.
REVENUE FORECAST: Third-quarter revenue is estimated to have grown 2.4% from a year earlier to Y1.138 trillion, according to the LSEG poll.
The stock has declined 0.7% so far this year to close at Y4,153 on Wednesday, following a 3.1% gain in 2024.
WHAT TO WATCH:
--For the fiscal year ending March, Takeda has projected that revenue will increase 5.1% to Y4.480 trillion and net profit will drop 53% to Y68.00 billion. Investors will be closely watching for any changes to the annual guidance.
--Second-quarter sales of ulcerative colitis drug Entyvio climbed 20% to Y238.9 billion and sales of plasma-derived products rose 20% to Y264.2 billion. Investors will be focusing on the pace of sales growth for key drugs.
--The company's operating profit margin improved to 15.7% in its second quarter from 13.8% the previous quarter. Investors will be paying attention to margin trends as businesses globally are dealing with relatively high inflation.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
January 29, 2025 04:10 ET (09:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。